Company profile
Canopy Growth Corp
NASDAQ:CGCMedicinal Chemicals and Botanical Products
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04577612 | phase2 | completed | 2020-09-01 | 2021-05-15 | Canopy Growth Corporation | A Randomized Controlled Test of the Effects of CHI-554 on Fear. |
| NCT05317013 | phase1 | terminated | 2022-05-01 | 2022-09-22 | Canopy Growth Corporation | CBD in Postmenopausal Women With Osteopenia |
| NCT04086342 | phase2 | withdrawn | 2020-01-24 | 2021-01-26 | Canopy Growth Corporation | CHI-902 for Treatment of Social Anxiety Disorder |
| NCT03984604 | phase2 | terminated | 2019-03-21 | 2020-06-17 | Canopy Growth Corporation | Investigation of the Efficacy and Safety of CHI-921 in Insomnia. |
| NCT05679830 | phase2 | completed | 2020-09-23 | 2021-09-23 | Canopy Growth Corporation | The Effects of CBD Isolate on Menstrual-Related Symptoms |
FDA applications (0)
No records yet.